The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke
Trial Parameters
Brief Summary
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent was obtained from the patient or their legally authorized representative prior to study participation. 2. Age 35-80. 3. Patients must exhibit neurological manifestations consistent with acute ischemic stroke, with a documented onset-to-intervention interval ranging from 24 to 72 hours at the time of scheduled initial administration of the investigational drug. 4. Verified by CT/MRI current hemispheric ischemic stroke. 5. NIHSS score ≥5 and ≤15 at screening. 6. Ability to comply with all protocol-specified procedures, prohibitions, and restrictions. 7. Willingness and ability to adhere to highly effective contraceptive methods as outlined in the study protocol. Exclusion Criteria: 1. Hemorrhagic stroke or hemorrhagic transformation of ischemic focus, traumatic brain injuries 2. Vertebrobasilar stroke and/or development of acute insufficiency syndromes in the arteries of the vertebrobasilar system 3. A patient with ischemic stroke who is a